Skip to content
DraconiticResearch
Search Sources API
190,332 studies31 sourcesUpdated 53 min ago
Peer-reviewedCC BYLasers in medical science

Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study.

  • Lynhda Nguyen1
  • Stefan W Schneider2
  • Katharina Herberger2
  1. 1Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. [email protected].
  2. 2Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Read full textPDFDOICite

Abstract

Androgenetic alopecia (AGA) is the most common form of hair loss and can significantly impact quality of life. Emerging non-invasive treatments include laser-assisted delivery of biomimetic growth factor-based serums. The aim of the study was to evaluate the safety and efficacy of non-ablative fractional laser (NAFL)-assisted delivery, with or without adjunct red light therapy, in patients with AGA. In this pilot study, patients were randomly assigned to: (I) NAFL-assisted serum delivery plus red light therapy (triple), (II) NAFL-assisted serum delivery alone (dual), or (III) NAFL plus red light therapy without serum (EBD-only). Primary outcomes were hair density and thickness. Secondary outcomes included patient satisfaction, tolerability, and adverse events. Hair density increased in all groups, with greater improvement in the triple (25.6 ± 7.0 %) and dual (22.7 ± 3.4 %) groups compared to EBD-only (4.9 ± 9.2 %). Hair thickness improved in both serum groups but not in the EBD-only group. Clinical outcomes were similar between triple and dual treatments, though satisfaction was higher with triple therapy. No severe adverse events occurred. Preliminary evidence suggests that NAFL-assisted delivery of biomimetic growth factors is a safe and effective non-invasive treatment for AGA.

Related

  1. Comparative effectiveness of novel laser-assisted technologies for treating peri-implantitis : A network meta-analysis of randomized controlled trials
    Zhe Wang, Jing Wen, Haoyang Li +2
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  2. Bouldering-Psychotherapy for treating depression in adolescents (BooSt): study protocol for a randomized controlled trial.
    Katharina Luttenberger, Carolin Donath, Lola Eversmann +13
    BMC pediatricsPeer-reviewedCC BYFull textPhysiologyEurope PMCPMC
  3. Impact of vasopressin-assisted laparoscopic endometrioma excision on ovarian reserve: a randomized controlled trial
    Jaehoon Lee, Eunhyang Park, Hyemin Park +4
    Frontiers in reproductive healthPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Optimizing motor functions in incomplete spinal cord injury with simultaneous application of transcranial direct current stimulation and virtual reality assisted treadmill training: a study protocol for a randomized controlled trial {1a}
    Garima Wadhwa, Pooja Anand, Priyanka Rishi
    TrialsPeer-reviewedCC BY-NC-ND 4.0Clinical trials & evidence synthesisCrossref
  5. Closed Versus Open Vent Port Techniques and the Disconnection Technique for Optimizing Lung Collapse With Bronchial Blockers in Video‐Assisted Thoracoscopic Surgery: A Randomized Controlled Trial
    Juan Yao, Ya‐Jing Chen, Fang‐Ming Shen +6
    The clinical respiratory journalPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{nguyen2026thulium,
  title = {{Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study.}},
  author = {Lynhda Nguyen and Stefan W Schneider and Katharina Herberger},
  journal = {Lasers in medical science},
  year = {2026},
  month = oct,
  doi = {10.1007/s10103-026-05066-1},
  url = {https://europepmc.org/article/MED/42911445},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study.
AU  - Lynhda Nguyen
AU  - Stefan W Schneider
AU  - Katharina Herberger
PY  - 2026
DA  - 2026/10/22
JO  - Lasers in medical science
DO  - 10.1007/s10103-026-05066-1
UR  - https://europepmc.org/article/MED/42911445
AB  - Androgenetic alopecia (AGA) is the most common form of hair loss and can significantly impact quality of life. Emerging non-invasive treatments include laser-assisted delivery of biomimetic growth factor-based serums. The aim of the study was to evaluate the safety and efficacy of non-ablative fractional laser (NAFL)-assisted delivery, with or without adjunct red light therapy, in patients with AGA. In this pilot study, patients were randomly assigned to: (I) NAFL-assisted serum delivery plus red light therapy (triple), (II) NAFL-assisted serum delivery alone (dual), or (III) NAFL plus red light therapy without serum (EBD-only). Primary outcomes were hair density and thickness. Secondary outcomes included patient satisfaction, tolerability, and adverse events. Hair density increased in all groups, with greater improvement in the triple (25.6 ± 7.0 %) and dual (22.7 ± 3.4 %) groups compared to EBD-only (4.9 ± 9.2 %). Hair thickness improved in both serum groups but not in the EBD-only group. Clinical outcomes were similar between triple and dual treatments, though satisfaction was higher with triple therapy. No severe adverse events occurred. Preliminary evidence suggests that NAFL-assisted delivery of biomimetic growth factors is a safe and effective non-invasive treatment for AGA.
SN  - 0268-8921
SN  - 1435-604X
ER  -